Mirum Pharmaceuticals Inc (NAS:MIRM)
$ 41.56 -0.47 (-1.12%) Market Cap: 2.02 Bil Enterprise Value: 2.06 Bil PE Ratio: 0 PB Ratio: 8.69 GF Score: 51/100

Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 06:30PM GMT
Release Date Price: $15.92 (+2.71%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Good afternoon. My name is Jeff Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 40th JPMorgan Healthcare Conference today with Mirum. I'm joined by the company's CEO, Chris Peetz, who's going to give a presentation on the company, and then we'll go into some Q&A. (Operator Instructions) So without any further delay, let me turn it over to Chris Peetz.

Christopher Peetz
Mirum Pharmaceuticals, Inc. - President, CEO & Director

Thanks, Jess. Thanks for hosting us this year as well. And I appreciate everybody's interest in Mirum Pharmaceuticals. It's an exciting time for us, and I'll go through some of our updates as well as a little background on our programs. But first, just to kick off, I'll be making forward-looking statements. So we would refer you to our SEC filings for more complete disclosure on risk factors and other information on the company. Calling out some page numbers as we go through the corporate deck here and starting on Page 3. Mirum is a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot